公开(公告)号：WO2006119284A3

公开(公告)日：2007-01-11

申请号：PCT/US2006016824

申请日：2006-05-03

Applicant: DEKK TEC INC ,  MORGAN LEE R

Inventor： MORGAN LEE ROY

IPC: A61K31/15 ,  A61K41/00 ,  C07C251/80 ,  C07C251/82

CPC classification number: C07C251/80 ,  C07C251/82

Abstract: Disclosed herein are compounds, compositions and methods for using such compounds and compositions in the treatment of hyperproliferative conditions, including precancerous and cancerous conditions. In one embodiment, the compounds include resonance modulating compounds that can be used in the method as a coupling agent that is capable of interacting with the immune system to monitor or stimulate immune function. Such resonance modulators have inherent electromagnetic properties that attract immune cells to a target area to which the resonance modulating agent has been applied. Electromagnetic properties (such as a voltage amplitude) of the target region are altered in the presence of the resonance modulator, and serve as an indicator of immune function. An external stimulus (such as an applied electromagnetic field) can also be applied to the resonance modulator to enhance its immune stimulating and attractant properties. Particular examples of resonance modulators are disclosed, and these substances generally possess resonating intramolecular dipole moments that are capable of electrostatic interaction with biological environments. In certain examples the compounds aggregate at sites of therapeutic action to enhance their therapeutic activity. In other examples the compounds stimulate platelet production.

Abstract translation: 本文公开了使用这些化合物和组合物来治疗过度增殖病症（包括癌前病变和癌症病症）的化合物，组合物和方法。 在一个实施方案中，所述化合物包括共振调节化合物，其可以在该方法中用作偶联剂，其能够与免疫系统相互作用以监测或刺激免疫功能。 这种共振调制剂具有将免疫细胞吸引到已经施加共振调节剂的目标区域的固有电磁特性。 在谐振调制器的存在下改变目标区域的电磁特性（如电压振幅），并且作为免疫功能的指标。 外部刺激（例如施加的电磁场）也可以应用于共振调制器以增强其免疫刺激和引诱特性。 公开了共振调制剂的具体实例，并且这些物质通常具有能够与生物环境静电相互作用的共振的分子内偶极矩。 在某些实例中，化合物在治疗作用的部位聚集以增强其治疗活性。 在其他实例中，化合物刺激血小板产生。

公开(公告)号：WO2007100888A3

公开(公告)日：2008-07-17

申请号：PCT/US2007005262

申请日：2007-03-02

Applicant: SIGA TECHNOLOGIES INC ,  HRUBY DENNIS E ,  BOLKEN TOVE ,  AMBERG SEAN ,  DAI DONGCHENG

Inventor： HRUBY DENNIS E ,  BOLKEN TOVE ,  AMBERG SEAN ,  DAI DONGCHENG

IPC: A61K31/16 ,  A61K31/38 ,  A61K31/405

CPC classification number: C07C251/86 ,  A61K31/165 ,  A61K31/343 ,  C07C251/76 ,  C07C251/82 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2603/20 ,  C07D209/40 ,  C07D307/68 ,  C07D333/22 ,  C07D333/38

Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, and Pichinde), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).

Abstract translation: 公开了通过施用治疗有效量的某些新化合物来治疗病毒感染的化合物，方法和药物组合物。 还公开了制备化合物的方法和使用该化合物的方法及其药物组合物。 特别地，公开了治疗和预防由出血热病毒引起的病毒感染，即，包括但不限于：链球菌科（Junin，Machupo，Guanarito，Sabia，Lassa，Tacaribe和Pichinde），丝状病毒科（埃博拉 马尔堡病毒），黄病毒科（黄热病，鄂木斯克出血热和Kyasanur森林病毒）和布尼瓦病毒（裂谷热）。

公开(公告)号：WO2007100888A2

公开(公告)日：2007-09-07

申请号：PCT/US2007/005262

申请日：2007-03-02

Applicant: SIGA TECHNOLOGIES, INC. ,  HRUBY, Dennis, E. ,  BOLKEN, Tove ,  AMBERG, Sean ,  DAI, Dongcheng

Inventor： HRUBY, Dennis, E. ,  BOLKEN, Tove ,  AMBERG, Sean ,  DAI, Dongcheng

CPC classification number: C07C251/86 ,  A61K31/165 ,  A61K31/343 ,  C07C251/76 ,  C07C251/82 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2603/20 ,  C07D209/40 ,  C07D307/68 ,  C07D333/22 ,  C07D333/38 ,  Y02A50/387 ,  Y02A50/397

Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, and Pichinde), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).

Abstract translation: 公开了通过施用治疗有效量的某些新化合物来治疗病毒感染的化合物，方法和药物组合物。 还公开了制备化合物的方法和使用该化合物的方法及其药物组合物。 特别地，公开了治疗和预防由出血热病毒引起的病毒感染，即，包括但不限于：链球菌科（Junin，Machupo，Guanarito，Sabia，Lassa，Tacaribe和Pichinde），丝状病毒科（埃博拉 马尔堡病毒），黄病毒科（黄热病，鄂木斯克出血热和Kyasanur森林病毒）和布尼瓦病毒（裂谷热）。

公开(公告)号：WO1996031464A1

公开(公告)日：1996-10-10

申请号：PCT/EP1996001308

申请日：1996-03-25

Applicant: BAYER AKTIENGESELLSCHAFT ,  SEITZ, Thomas ,  STENZEL, Klaus

Inventor： BAYER AKTIENGESELLSCHAFT

IPC: C07C251/86

CPC classification number: C07D307/81 ,  A01N37/50 ,  C07C251/82 ,  C07C251/86 ,  C07D307/54 ,  C07D333/24 ,  C07D333/60

Abstract: The invention concerns hydrazonoacetic acid amides of general formula (I), a process for producing them, and the use of the said amides as pesticides. In the formula shown, the following meanings apply: A stands for a simple bond or optionally substituted alkylene; Q stands for oxygen or sulphur; R stands for optionally substituted cycloalkyl, cycloalkenyl, aryl or heterocyclyl; R stands for hydrogen or optionally substituted alkyl, cycloalkyl, cycloalkenyl, aryl or heterocyclyl; R and R are identical or different and each stand for hydrogen or optionally substituted alkyl or cycloalkyl; R and R together with the nitrogen atom to which they are bound form an optionally substituted heterocyclyl ring; R stands for optionally substituted cycloalkyl, cycloalkenyl, aryl or heterocyclyl.

Abstract translation: 本发明涉及式（I）通式Hydrazonoessigsäureamide，其制备方法以及用作杀虫剂的方法，其中A表示单键或任选取代的亚烷基，Q表示氧或硫，R <1>，任选取代的环烷基 环烯基，芳基或杂环基，R <2>是氢或任选被取代的烷基，环烷基，环烯基，芳基或杂环基，R <3>，R <4>相同或不同且各自表示氢或在每种情况下任选取代的烷基 或环烷基，R <2>和R <3>与氮原子一起形成它们所连接形成任选取代的杂环基，R <5>是任选取代的Cycloakyl，环烯基，芳基或杂环基。

公开(公告)号：WO2013087770A1

公开(公告)日：2013-06-20

申请号：PCT/EP2012/075386

申请日：2012-12-13

Applicant: L'OREAL

Inventor： SABELLE, Stéphane

IPC: C07C215/82 ,  C07C225/28 ,  A61K8/41 ,  A61Q5/10 ,  C07C251/82

CPC classification number: A61K8/355 ,  A61K8/41 ,  A61K8/411 ,  A61K8/415 ,  A61K2800/10 ,  A61Q5/065 ,  A61Q5/10 ,  C07C215/82 ,  C07C225/28 ,  C07C251/82 ,  C09B23/0066

Abstract: The present invention relates to quinone direct dyes of formula (I) below, organic or mineral acid or base salts thereof,tautomeric forms, optical isomers or geometrical isomers thereof and/or solvates thereof: and also to the use thereof for dyeing keratin fibres, in particular human keratin fibres such as the hair. The invention also relates to a composition for dyeing keratin fibres, comprising such direct dyes in a suitable dyeing medium. Similarly, a subject of the present invention is a process for dyeing keratin fibres, using the said dye composition.

Abstract translation: 本发明涉及以下式（I）的醌直接染料，其有机或无机酸或其盐，互变异构形式，光学异构体或其几何异构体和/或溶剂合物：以及其用于染色角蛋白纤维的用途， 特别是人角蛋白纤维如头发。 本发明还涉及用于染色角蛋白纤维的组合物，其在合适的染色介质中包含这种直接染料。 类似地，本发明的主题是使用所述染料组合物染色角蛋白纤维的方法。

公开(公告)号：WO2010072632A1

公开(公告)日：2010-07-01

申请号：PCT/EP2009/067286

申请日：2009-12-16

Applicant: SYNGENTA LIMITED ,  HODGES, George, Robert ,  MITCHELL, Lisa ,  ROBINSON, Alan, James

Inventor： HODGES, George, Robert ,  MITCHELL, Lisa ,  ROBINSON, Alan, James

IPC: C07D231/08 ,  C07C231/08

CPC classification number: C07D333/28 ,  C07C25/18 ,  C07C43/192 ,  C07C49/693 ,  C07C251/82 ,  C07D231/14

Abstract: The present invention relates to methods of initiating a reaction represented by scheme (1), wherein Q is optionally substituted aryl or optionally substituted heteroaryl; X is halogen or a sulphonate; P is an organic radical; R is hydrogen or an organic radical; wherein the catalyst comprises copper and a ligand; comprising providing the compound of formula III in liquid form prior to contacting the compound of formula III with the catalyst.

Abstract translation: 本发明涉及引发由方案（1）表示的反应的方法，其中Q是任选取代的芳基或任选取代的杂芳基; X是卤素或磺酸盐; P是有机基团; R是氢或有机基团; 其中所述催化剂包含铜和配体; 在将式III化合物与催化剂接触之前，提供液态的式III化合物。

公开(公告)号：WO2006119284A2

公开(公告)日：2006-11-09

申请号：PCT/US2006/016824

申请日：2006-05-03

Applicant: DEKK-TEC, INC. ,  MORGAN, Lee Roy

Inventor： MORGAN, Lee Roy

IPC: A61K31/15 ,  A61K41/00 ,  C07C251/80 ,  C07C251/82

CPC classification number: C07C251/80 ,  C07C251/82

Abstract: Disclosed herein are compounds, compositions and methods for using such compounds and compositions in the treatment of hyperproliferative conditions, including precancerous and cancerous conditions. In one embodiment, the compounds include resonance modulating compounds that can be used in the method as a coupling agent that is capable of interacting with the immune system to monitor or stimulate immune function. Such resonance modulators have inherent electromagnetic properties that attract immune cells to a target area to which the resonance modulating agent has been applied. Electromagnetic properties (such as a voltage amplitude) of the target region are altered in the presence of the resonance modulator, and serve as an indicator of immune function. An external stimulus (such as an applied electromagnetic field) can also be applied to the resonance modulator to enhance its immune stimulating and attractant properties. Particular examples of resonance modulators are disclosed, and these substances generally possess resonating intramolecular dipole moments that are capable of electrostatic interaction with biological environments. In certain examples the compounds aggregate at sites of therapeutic action to enhance their therapeutic activity. In other examples the compounds stimulate platelet production.

Abstract translation: 本文公开了使用这些化合物和组合物来治疗过度增殖病症（包括癌前病变和癌症病症）的化合物，组合物和方法。 在一个实施方案中，所述化合物包括共振调节化合物，其可以在该方法中用作偶联剂，其能够与免疫系统相互作用以监测或刺激免疫功能。 这种共振调制剂具有将免疫细胞吸引到已经施加共振调节剂的目标区域的固有电磁特性。 在谐振调制器的存在下改变目标区域的电磁特性（如电压振幅），并且作为免疫功能的指标。 外部刺激（例如施加的电磁场）也可以应用于共振调制器以增强其免疫刺激和引诱特性。 公开了共振调制剂的具体实例，并且这些物质通常具有能够与生物环境静电相互作用的共振的分子内偶极矩。 在某些实例中，化合物在治疗作用的部位聚集以增强其治疗活性。 在其他实例中，化合物刺激血小板产生。

公开(公告)号：WO2017002120A1

公开(公告)日：2017-01-05

申请号：PCT/IL2016/050702

申请日：2016-06-30

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： KRIZHANOVSKY, Valery ,  GAL, Hilah

IPC: A61P29/00 ,  A61P1/16 ,  A61P17/00 ,  A61P43/00 ,  A61K31/33 ,  A61K31/4427 ,  A61K31/4709 ,  A61K31/429 ,  A61K31/015 ,  A61K31/357 ,  A61K31/7004 ,  C07H11/00 ,  C07D493/02 ,  C07D487/02 ,  C07D213/84 ,  C07C205/16 ,  C07C205/40 ,  C07D409/12 ,  C07D217/24 ,  C07C49/603 ,  C07D513/02 ,  C07D257/04 ,  C07D213/71 ,  C07D417/12 ,  C07D277/62 ,  C07D417/04 ,  C07D333/20 ,  C07D277/70 ,  A61Q19/08 ,  C07H13/02 ,  A61K31/635

CPC classification number: A61K31/015 ,  A61K31/33 ,  A61K31/357 ,  A61K31/429 ,  A61K31/4427 ,  A61K31/4709 ,  A61K31/635 ,  A61K31/7004 ,  A61Q19/08 ,  C07C49/747 ,  C07C49/813 ,  C07C205/16 ,  C07C205/40 ,  C07C251/38 ,  C07C251/82 ,  C07C2601/16 ,  C07C2603/28 ,  C07D213/71 ,  C07D213/84 ,  C07D217/24 ,  C07D257/04 ,  C07D277/62 ,  C07D277/70 ,  C07D333/20 ,  C07D409/12 ,  C07D417/04 ,  C07D417/12 ,  C07D487/02 ,  C07D493/02 ,  C07D513/02 ,  C07H13/00

Abstract: Compounds useful for selectively eliminating senescent cells, compositions comprising same and uses thereof in treating diseases and disorders in which selective elimination of senescent cells is beneficial are provided. The compounds are selectively represented by the following Formulae (I) and (II); with the variables being as defined in the specification. Also provided is a screening assay for identifying compounds that selectively inhibit senescent cells.

Abstract translation: 提供了用于选择性消除衰老细胞的化合物，包含其的组合物及其用于治疗其中选择性消除衰老细胞有益的疾病和病症的用途。 所述化合物由下式（I）和（II）选择性地表示; 变量如规范中所定义。 还提供了用于鉴定选择性抑制衰老细胞的化合物的筛选测定。

公开(公告)号：WO2015064698A1

公开(公告)日：2015-05-07

申请号：PCT/JP2014/078920

申请日：2014-10-30

Applicant: 日本ゼオン株式会社

Inventor： 坂本　圭 ,  奥山　久美

IPC: C08F20/38 ,  C08F20/36 ,  G02B5/30

CPC classification number: C07D277/82 ,  C07C251/82 ,  C07C251/86 ,  C07D277/62 ,  C08F222/1006 ,  C09K19/3838 ,  G02B1/111 ,  G02B5/30

Abstract: 　本発明は、式（Ｉ）で示される重合性化合物、該重合性化合物及び重合開始剤を含有する重合性組成物、前記重合性化合物又は重合性組成物を重合して得られる高分子、並びに該高分子を構成材料とする光学異方体である。式（１）中、Ｙ １ ～Ｙ ９ は、－Ｏ－、－Ｓ－、－Ｏ－Ｃ（＝Ｏ）－、－Ｃ（＝Ｏ）－Ｏ－等を、Ｇ １ 、Ｇ ２ は炭素数１～２０の二価の鎖状脂肪族基等を、Ｚ １ ～Ｚ ３ は炭素数２～１０のアルケニル基等を、Ａ ｘ は下記式（ＩＩ）で表される基（Ｘは酸素原子、硫黄原子等を表す。）を、Ｄは炭素数１～２０のアルキレン基等を、Ａ １ は三価の芳香族基等を、Ａ ２ 、Ａ ３ は炭素数３～３０の二価の脂環式炭化水素基等を、Ａ ４ 、Ａ ５ は炭素数４～３０の二価の芳香族基等を、Ｑ １ は炭素数１～６のアルキル基等を、ｍ、ｎは０又は１を表す。

Abstract translation: 本发明提供由式（I）表示的可聚合化合物，含有可聚合化合物和聚合引发剂的可聚合组合物，通过聚合可聚合化合物或可聚合组合物制备的聚合物和包含聚合物作为构成材料的光学异构体。 在式（1）中，Y 1至Y 9表示-O-，-S-，-OC（= O） - ， - C（= O）-O-等，G 1和G 2表示C 1-20二价链脂族基团 等等，Z1至Z3表示C2-10烯基等，AX表示由下式（II）表示的基团（其中X表示氧原子，硫原子等），D表示C1-20 亚烷基等，A1表示三价芳族基团，A2和A3表示C3-30二价脂环族烃基等，A4和A5表示C4-30二价芳基等，Q1表示C1-6烷基 基团等，m和n分别为0或1。

公开(公告)号：WO2010072631A1

公开(公告)日：2010-07-01

申请号：PCT/EP2009/067283

申请日：2009-12-16

Applicant: SYNGENTA LIMITED ,  HODGES, George, Robert ,  MITCHELL, Lisa ,  ROBINSON, Alan, James

Inventor： HODGES, George, Robert ,  MITCHELL, Lisa ,  ROBINSON, Alan, James

IPC: C07D231/12

CPC classification number: C07D333/28 ,  C07C25/18 ,  C07C43/192 ,  C07C49/693 ,  C07C251/82 ,  C07D231/14

Abstract: The present invention relates to methods of preparing compounds of formula (I) comprising the step of reacting the corresponding amide with the corresponding substituted aryl in the presence of a catalyst, which catalyst comprises copper and a ligand, Y is CHCHR 6 (R 7 ) or C=C(A)Z, CY 2 (R 2 )Y 3 (R 3 ), C=N-NR 4 (R 5 ); Y 2 and Y 3 are, independently, O, S, N; A and Z are, independently, C 1-6 alkyl; R 1 is CF 3 or CF 2 H; R 2 and R 3 are, independently, C 1-8 alkyl, wherein R 2 and R 3 are optionally joined to form a 5-8 membered ring; R 4 and R 5 are, independently, C 1-8 alkyl; B is a single bond or a double bond; R 6 and R 7 are, independently, hydrogen or C 1-6 alkyl.

Abstract translation: 本发明涉及制备式（I）化合物的方法，其包括在催化剂存在下使相应的酰胺与相应的取代的芳基反应的步骤，该催化剂包含铜和配体，Y是CHCHR6（R7）或C = C（A）Z，CY2（R2）Y3（R3），C = N-NR4（R5）; Y 2和Y 3独立地是O，S，N; A和Z独立地为C 1-6烷基; R1为CF3或CF2H; R2和R3独立地为C1-8烷基，其中R2和R3任选地连接形成5-8元环; R 4和R 5独立地是C 1-8烷基; B是单键或双键; R6和R7独立地是氢或C1-6烷基。